Product Description
Bortezomib is used to treat people with multiple myeloma (a type of cancer of the bone marrow). Bortezomib is also used to treat people with mantle cell lymphoma (a fast-growing cancer that begins in the cells of the immune system). Bortezomib is in a class of medications called antineoplastic agents. It works by killing cancer cells. (Sourced from: https://medlineplus.gov/druginfo/meds/a607007.html)
Mechanisms of Action: Proteasome Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Lymphoma | Multiple Myeloma | Lymphoma | Multiple Myeloma
Known Adverse Events: Neuralgia | Anemia | Leukopenia | Lymphopenia | Thrombocytopenia | Neutropenia | Anorexia | Constipation | Diarrhea
Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Lithuania, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Puerto Rico, Romania, Russia, Singapore, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 64
Highest Development Phases
Phase 3: Amyloidosis|Multiple Myeloma
Phase 2: Acute Myeloid Leukemia|Acute Promyelocytic Leukemia|Acute Radiation Syndrome|Blood Protein Disorders|Diffuse Large B-Cell Lymphoma|Kidney Diseases|Large-Cell Immunoblastic Lymphoma|Leukemia, Plasma Cell|Lymphoma, Non-Hodgkin|Monoclonal Gammopathy of Undetermined Significance|Myelodysplastic Syndrome|Neuroblastoma|Pancreatic Cancer|Paraproteinemias|Plasmablastic Lymphoma|Plasmacytoma|Stem Cell Transplant|Waldenstrom Macroglobulinemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CA057-001 | P3 |
Unknown Status |
Multiple Myeloma |
2034-07-28 |
|
| 2024-516905-22-00 | P3 |
Unknown Status |
Multiple Myeloma |
2031-12-31 |
|
| GEM2017FIT | P3 |
Active, not recruiting |
Multiple Myeloma |
2031-06-25 |
|
| jRCT2071230097 | P3 |
Not yet recruiting |
Multiple Myeloma |
2030-02-28 |